TrialJAMA oncology2024

Mesenchymal Stem Cells for Prophylaxis of Chronic Graft-vs-Host Disease After Haploidentical Hematopoietic Stem Cell Transplant: An Open-Label Randomized Clinical Trial.

Ruihao Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.